Molecular pathways associated with aggressiveness of papillary thyroid cancer
- PMID: 24955023
- PMCID: PMC4064555
- DOI: 10.2174/1389202915999140404100958
Molecular pathways associated with aggressiveness of papillary thyroid cancer
Abstract
The most common thyroid malignancy is papillary thyroid cancer (PTC). Mortality rates from PTC mainly depend on its aggressiveness. Geno- and phenotyping of aggressive PTC has advanced our understanding of treatment failures and of potential future therapies. Unraveling molecular signaling pathways of PTC including its aggressive forms will hopefully pave the road to reduce mortality but also morbidity from this cancer. The mitogen-activated protein kinase and the phosphatidylinositol 3-kinase signaling pathway as well as the family of RAS oncogenes and BRAF as a member of the RAF protein family and the aberrant expression of microRNAs miR-221, miR-222, and miR-146b all play major roles in tumor initiation and progression of aggressive PTC. Small molecule tyrosine kinase inhibitors targeting BRAF-mediated events, vascular endothelial growth factor receptors, RET/PTC rearrangements, and other molecular targets, show promising results to improve treatment of radioiodine resistant, recurrent, and aggressive PTC.
Keywords: BRAF; P13/Akt; Papillary thyroid cancer; Signaling; Tyrosine kinase; VEGF..
Figures

Similar articles
-
MicroRNA-146b: A Novel Biomarker and Therapeutic Target for Human Papillary Thyroid Cancer.Int J Mol Sci. 2017 Mar 15;18(3):636. doi: 10.3390/ijms18030636. Int J Mol Sci. 2017. PMID: 28294980 Free PMC article. Review.
-
[The mitogen-activated protein kinase (MAPK) signaling pathway in papillary thyroid cancer. From the molecular bases to clinical practice].Endocrinol Nutr. 2009 Apr;56(4):176-86. doi: 10.1016/S1575-0922(09)70982-9. Epub 2009 Jun 11. Endocrinol Nutr. 2009. PMID: 19627734 Review. Spanish.
-
Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma.Cancer. 2010 Jun 15;116(12):2974-83. doi: 10.1002/cncr.25061. Cancer. 2010. PMID: 20564403
-
MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma.Ann Surg Oncol. 2011 Jul;18(7):2035-41. doi: 10.1245/s10434-011-1733-0. Epub 2011 May 3. Ann Surg Oncol. 2011. PMID: 21537871 Free PMC article.
-
RET/PTC rearrangements preferentially occurred in papillary thyroid cancer among atomic bomb survivors exposed to high radiation dose.Cancer Res. 2008 Sep 1;68(17):7176-82. doi: 10.1158/0008-5472.CAN-08-0293. Cancer Res. 2008. PMID: 18757433
Cited by
-
Mps1 is associated with the BRAFV600E mutation but does not rely on the classic RAS/RAF/MEK/ERK signaling pathway in thyroid carcinoma.Oncol Lett. 2018 Jun;15(6):9978-9986. doi: 10.3892/ol.2018.8561. Epub 2018 Apr 24. Oncol Lett. 2018. PMID: 29805692 Free PMC article.
-
Roles of phosphatidylinositol 3-kinase regulatory subunit alpha, activator protein-1, and programmed cell death 4 in diagnosis of papillary thyroid carcinoma.Tumour Biol. 2016 May;37(5):6519-26. doi: 10.1007/s13277-015-4476-x. Epub 2015 Dec 4. Tumour Biol. 2016. PMID: 26637226
-
The micropapillary/hobnail variant of papillary thyroid carcinoma: A review of series described in the literature compared to a series from one southern Italy pathology institution.Rev Endocr Metab Disord. 2016 Dec;17(4):521-527. doi: 10.1007/s11154-016-9398-4. Rev Endocr Metab Disord. 2016. PMID: 27896649 Review.
-
Predictive factors of contralateral occult carcinoma in patients with papillary thyroid carcinoma: a retrospective study.Gland Surg. 2020 Aug;9(4):872-878. doi: 10.21037/gs-19-157. Gland Surg. 2020. PMID: 32953595 Free PMC article.
-
Association of BRAF V600E Mutation and MicroRNA Expression with Central Lymph Node Metastases in Papillary Thyroid Cancer: A Prospective Study from Four Endocrine Surgery Centers.Thyroid. 2016 Apr;26(4):532-42. doi: 10.1089/thy.2015.0378. Epub 2016 Mar 7. Thyroid. 2016. PMID: 26950846 Free PMC article.
References
-
- Carcangiu ML, Zampi G, Pupi A, Castagnoli A, Rosai J. Papillary carcinoma of the thyroid.A clinicopathologic study of 241 cases treated at the University of Floence Italy. Cancer . 1985; 55(4):805–828. - PubMed
-
- Hefer T, Joachims HZ, Hashmonai M, Ben-Arieh Y, Brown J. Highly aggressive behavior of occult papillary thyroid carcinoma. J. Laryngol. Otol. 1995;109(11):1109–1112. - PubMed
-
- Reiners C. Thyroid cancer in 2013: Advances in our understanding of differentiated thyroid cancer. Nat. Rev. Endocrinol. 2014;10(2):69–70. - PubMed
-
- Antonelli A, Miccoli P, Fallahi P, Grosso M, Nesti C, Spinelli C, Ferrannini E. Role of neck ultrasonography in the follow-up of children operated on for thyroid papillary cancer. Thyroid. 2003;13(5):479–484. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous